Compare MakeMyTrip Ltd (MMYT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Moderna, Inc. — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 19.2× MakeMyTrip Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Moderna, Inc. for 59 Days on average.
| MMYT | MRNA | |
|---|---|---|
Market Cap | $4.09B | $78.65B |
Volume | 1,828,010 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $203.46 |
52-Week Low | $36.30 | $22.36 |
Typical Hold Time | 12 Days | 59 Days |
Enterprise Value | $4.75B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $43.53, up 0.28% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported mixed quarterly earnings, with a Q1 2026 beat and Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, but net income margin compressed to 3.23% in 2026. Analyst consensus is strongly bullish with a $77.00 price target, though institutional selling has been noted recently.
The outlook is bifurcated: strong analyst support and a potential Indian listing offer upside, but declining profitability, high P/E ratio, and bearish technicals pose risks. Investors face volatility from operational execution and travel industry cyclicality against a backdrop of Wall Street optimism.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
